| Kristen Koconis, MD | |
|
100 N Academy Ave, Danville, PA 17822-2360 | |
| (570) 271-6301 | |
| (570) 271-5976 |
| Full Name | Kristen Koconis |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 19 Years |
| Location | 100 N Academy Ave, Danville, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134346539 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | MD439938 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| York Hospital | York, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| York Hospital | 6406766781 | 169 |
News Archive
According to a study published in the April 6 issue of the Journal of the American Medical Association JAMA, receiving higher prescribed doses of opioid prescriptions is associated with an increased risk of opioid overdose death, but receiving both as-needed and regularly scheduled doses is not associated with overdose risk.
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
The mystery of why multiple sclerosis (MS) tends to go into remission while women are pregnant may be the secret to overcoming the devastating neurodegenerative disease, according to University of Calgary researchers who have shown that a pregnancy-related hormone is responsible for rebuilding the protective coating around nerve cells.
The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.
› Verified 6 days ago
| Entity Name | York Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376528398 PECOS PAC ID: 6406766781 Enrollment ID: O20040812001065 |
News Archive
According to a study published in the April 6 issue of the Journal of the American Medical Association JAMA, receiving higher prescribed doses of opioid prescriptions is associated with an increased risk of opioid overdose death, but receiving both as-needed and regularly scheduled doses is not associated with overdose risk.
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
The mystery of why multiple sclerosis (MS) tends to go into remission while women are pregnant may be the secret to overcoming the devastating neurodegenerative disease, according to University of Calgary researchers who have shown that a pregnancy-related hormone is responsible for rebuilding the protective coating around nerve cells.
The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kristen Koconis, MD 100 N Academy Ave, Danville, PA 17822-4903 Ph: (570) 271-6144 | Kristen Koconis, MD 100 N Academy Ave, Danville, PA 17822-2360 Ph: (570) 271-6301 |
News Archive
According to a study published in the April 6 issue of the Journal of the American Medical Association JAMA, receiving higher prescribed doses of opioid prescriptions is associated with an increased risk of opioid overdose death, but receiving both as-needed and regularly scheduled doses is not associated with overdose risk.
Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use of its products.
The mystery of why multiple sclerosis (MS) tends to go into remission while women are pregnant may be the secret to overcoming the devastating neurodegenerative disease, according to University of Calgary researchers who have shown that a pregnancy-related hormone is responsible for rebuilding the protective coating around nerve cells.
The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.
› Verified 6 days ago
Dr. Tana M. Shaffer, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6301 | |
Leslie C. Scott, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-560-1628 Fax: 570-560-1628 | |
Dr. Mary L. Strickland, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6301 | |
Clara Jean Chudow, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6301 Fax: 570-271-5976 | |
Dr. Faruq Mahmud, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6301 | |
Dr. Marta J. Carleton, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6301 | |
Arbab Iqbal, Radiology Medicare: Accepting Medicare Assignments Practice Location: Geisinger Medical Ctr, 100 North Academy Avenue, Danville, PA 17822 Phone: 570-271-6211 |